The purpose of this study is to evaluate the safety, tolerability, and immunogenicity of an HIV vaccine (gp145 C.6980) with aluminum hydroxide adjuvant in healthy, HIV-1-uninfected adults in the United States.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Pain and/or Tenderness
Timeframe: Measured through 7 days after first vaccination at Month 0
Number of Participants Reporting Local Reactogenicity Signs and Symptoms:Erythema and/or Induration
Timeframe: Measured through 7 days after first vaccination at Month 0
Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms
Timeframe: Measured through 7 days after first vaccination at Month 0
Number of Participants Reporting Adverse Events (AEs), by Severity Grade
Timeframe: Measured through 30 days after first vaccination at Month 0
Number of Participants Reporting Adverse Events (AEs), by Relationship to Study Product
Timeframe: Measured through 30 days after first vaccination at Month 0
Number of Participants Reporting Serious Adverse Events (SAEs)
Timeframe: Measured through 30 days after first vaccination at Month 0
Chemistry and Hematology Laboratory Measures With Grade 1 or Higher, Through First Vaccination
Timeframe: Measured at 2 weeks after first vaccination
Hematology Laboratory Measures: WBC, Neutrophils , Lymphocytes and Platelets
Timeframe: Measured at 2 weeks after first vaccination
Chemistry Laboratory Measures: Hemoglobin, Creatinine
Timeframe: Measured at 2 weeks after first vaccination
Chemistry Laboratory Measures: ALT
Timeframe: Measured at 2 weeks after first vaccination